Zydus Seeks EUA for ZyCoV-D Against COVID-19 in India
- The company has applied for emergency use authorization to the DCGI for ZyCoV-D- which is the world's first plasmid DNA vaccine for COVID-19
- Zydus conducted a clinical trial for its ZyCoV-D in the adolescent population aged 12-18yrs. in India over 50 centers. The vaccine is safe and well-tolerated and showed 66% efficacy for symptomatic RT-PCR positive cases.
- The vaccine reaffirms its efficacy against the new mutant strains especially the delta variant. ZyCoV-D is a three-dose- intradermal vaccine- and is needle-free- leading to a reduction in any side effects. The company plans to manufacture 10-12 crore doses annually
| Ref: Zydus | Image: PR Newswire
This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at email@example.com